PsychedelicNewsBreaks – Cybin Corp. Focused on Advancing New Products Amid Positive Research in Psychedelics

Cybin Corp., an exemplary Canada-based, life-science company focused on the development of pharmaceutical-grade psilocybin products, is at the forefront of change in an era open to exploring psychedelic treatment options where big pharma has failed. Started in the 1940s, but kiboshed in the 1960s with President Richard Nixon’s war on drugs, researchers have once again picked up the study of psychedelics in the treatment of mental health conditions. Research is showing positive results for many indications and disorders including depression, anxiety, PTSD, addictions, ADHD and more. A recent article discussing this reads, “Cybin believes that psychedelic substances derived from mushrooms can work as boosters for the brain, potentially rebuilding pathways and breaking negative patterns. Today more than 700 million people around the world struggle with mental illness, addiction or eating disorders — all areas where the benefits of psychedelic substances is being studied. What’s more, even though over 40 million Americans are taking psychiatric drugs, big pharma has not produced any new drug innovations in the last ten years (http://ibn.fm/f8BH4).”

To view the full article, visit http://ibn.fm/hV2Zx

About Cybin Corp.

Cybin is a mushroom life-science company advancing psychedelic and nutraceutical-based products. The company expects to launch psilocybin-based products in jurisdictions where the substance is not prohibited. Simultaneously, the company is structuring and supporting clinical studies across North America and other regions through strategic academic and institutional partnerships. For more information, visit www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://ibn.fm/Cybin

About PsychedelicNewsBreaks

PsychedelicNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of PsychedelicNewsWire (PNW). NNB keeps you up-to-date on active US Public Companies complementary to PNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. PNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled visibility, recognition and brand awareness. PNW is where news, content and information converge.

Please see full disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/disclaimer/

PsychedelicNewsWire (PNW)
San Francisco, CO
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com